Sutro Biopharma (STRO) Free Cash Flow (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Free Cash Flow data on file, last reported at -$26.6 million in Q4 2025.

• For the quarter ending Q4 2025, Free Cash Flow rose 64.11% year-over-year to -$26.6 million; the trailing twelve-month figure through Dec 2025 stood at -$178.9 million (up 8.07% YoY), and the FY2025 full-year result was -$178.9 million, up 8.07% from the prior year.
• Free Cash Flow rose to -$26.6 million in Q4 2025, from -$39.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $67.8 million in Q3 2022 to a low of -$74.2 million in Q4 2024.
• A 5-year average of -$29.0 million and a median of -$32.0 million in 2023 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow soared 369.23% in 2022 and slumped 622.81% in 2024, its largest moves.
• Tracing STRO's Free Cash Flow over 5 years: stood at -$34.7 million in 2021, then jumped by 35.61% to -$22.4 million in 2022, then jumped by 163.41% to $14.2 million in 2023, then tumbled by 622.81% to -$74.2 million in 2024, then soared by 64.11% to -$26.6 million in 2025.
• Business Quant data shows STRO's Free Cash Flow at -$26.6 million in Q4 2025, -$39.7 million in Q3 2025, and -$44.7 million in Q2 2025.